BerandaCTSO • NASDAQ
add
Cytosorbents Corp
$0,84
Setelah Jam Perdagangan Normal:(1,00%)+0,0084
$0,85
Tutup: 23 Des, 16.28.15 GMT-5 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$0,92
Rentang hari
$0,81 - $0,92
Rentang tahun
$0,70 - $1,82
Kapitalisasi pasar
45,72 jt USD
Volume Rata-Rata
160,02 rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Pendapatan | 9,39 jt | 6,58% |
Biaya operasional | 9,61 jt | -24,74% |
Laba bersih | -2,33 jt | 74,61% |
Margin laba bersih | -24,86 | 76,17% |
Penghasilan per saham | -0,08 | 61,90% |
EBITDA | -3,95 jt | 41,58% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 5,69 jt | -31,99% |
Total aset | 47,80 jt | 0,48% |
Total liabilitas | 34,80 jt | 19,76% |
Total ekuitas | 13,00 jt | — |
Saham yang beredar | 54,68 jt | — |
Harga terhadap nilai buku | 3,81 | — |
Tingkat pengembalian aset | -21,40% | — |
Tingkat pengembalian modal | -26,00% | — |
Arus Kas
Perubahan kas bersih
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Laba bersih | -2,33 jt | 74,61% |
Kas dari operasi | -2,46 jt | 52,73% |
Kas dari investasi | -298,35 rb | -15,77% |
Kas dari pembiayaan | -99,03 rb | -115,27% |
Perubahan kas bersih | -2,77 jt | 42,13% |
Arus kas bebas | -1,31 jt | 53,63% |
Tentang
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.
CytoSorbents sells a cytokine adsorbing column — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood.
The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns, which failed to show significance in a clinical trial for sepsis. The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy. Clinicaltrials.gov is giving an overview over running research projects.
CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins. Wikipedia
Didirikan
1997
Situs
Karyawan
186